Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma

被引：0
|
作者：
Engert, Andreas [1 ]
Taylor, Fiona [2 ]
Bennett, Bryan [3 ]
Hirji, Ishan [4 ]
Cocks, Kim [3 ]
McDonald, Jeffrey [2 ]
Mann, Erin [2 ]
Kato, Kazunobu [4 ]
Cella, David [5 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
[2] Adelphi Values, Boston, MA USA
[3] Adelphi Values, Bollington, England
[4] Bristol Myers Squibb Co, Princeton, NJ USA
[5] Northwestern Univ, Evanston, IL 60208 USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1831.1831
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1831
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
    Zinzani, Pier Luigi
    Ramchandren, Radhakrishnan
    Santoro, Armando
    Paszkiewicz-Kozik, Ewa
    Gasiorowski, Robin
    Johnson, Nathalie A.
    de Oliveira, Jose S. R.
    Buccheri, Valeria
    Perini, Guilherme Fleury
    Dickinson, Michael
    McDonald, Andrew
    Ozcan, Muhit
    Sekiguchi, Naohiro
    Zhu, Ying
    Raut, Monika
    Saretsky, Todd L.
    Nahar, Akash
    Kuruvilla, John
    BLOOD ADVANCES, 2022, 6 (02) : 590 - 599
  • [22] Patient-Reported Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab Monotherapy, Results of a Phase 2 Study
    von Tresckow, Bastian
    Fanale, Michelle A.
    Ardeshna, Kirit M.
    Chen, Robert W.
    Meissner, Julia
    Morschhauser, Franck
    Moskowitz, Craig H.
    Zinzani, Pier Luigi
    Giezek, Hilde
    Balakumaran, Arun
    Raut, Monika
    Vo, Thao
    Brice, Pauline
    BLOOD, 2017, 130
  • [23] Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
    von Tresckow, Bastian
    Fanale, Michelle
    Ardeshna, Kirit M.
    Chen, Robert
    Meissner, Julia
    Morschhauser, Franck
    Moskowitz, Craig
    Zinzani, Pier Luigi
    Giezek, Hilde
    Balakumaran, Arun
    Vo, Thao T.
    Raut, Monika
    Brice, Pauline
    LEUKEMIA & LYMPHOMA, 2019, 60 (11) : 2705 - 2711
  • [24] Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
    Momotow, Jesko
    Goergen, Helen
    Behringer, Karolin
    Broeckelmann, Paul J.
    Borchmann, Sven
    Tresckow, Bastian V.
    Kobe, Carsten
    Engert, Andreas
    Sasse, Stephanie
    HEMASPHERE, 2019, 3 (05):
  • [25] Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
    Maruyama, Dai
    Hatake, Kiyohiko
    Kinoshita, Tomohiro
    Fukuhara, Noriko
    Choi, Ilseung
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Terui, Yasuhito
    Higuchi, Yusuke
    Onishi, Yasushi
    Abe, Yasunobu
    Kobayashi, Tsutomu
    Shirasugi, Yukari
    Tobinai, Kensei
    CANCER SCIENCE, 2017, 108 (05) : 1007 - 1012
  • [26] NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: 2-YEAR FOLLOW-UP IN THE CHECKMATE 205 STUDY
    Domingo-Domenech, E.
    Ramchandren, R.
    Rueda, A.
    Trne
    Ny, M.
    Feldman, T.
    Hun, Lee J.
    Provencio, M.
    Sillaber, C.
    Cohen, J. B.
    Savage, K. J.
    Willenbacher, W.
    Sumbul, A.
    Sacchi, M.
    Armand, P.
    Ansell, S.
    HAEMATOLOGICA, 2019, 104 : 21 - 22
  • [27] NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL
    Engert, A.
    Fanale, M.
    Santoro, A.
    Armand, P.
    Ansell, S.
    Zinzani, P. L.
    Timmerman, J.
    Collins, G.
    Ramchandren, R.
    Cohen, J.
    De Boer, J. P.
    Kuruvilla, J.
    Savage, K.
    Trneny, M.
    Rodig, S.
    Shipp, M.
    Kato, K.
    Sumbul, A.
    Farsaci, B.
    Younes, A.
    HAEMATOLOGICA, 2017, 102 : 145 - 145
  • [28] A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma
    Hanel, Walter
    Shindiapina, Polina
    Bond, David A.
    Sawalha, Yazeed
    Epperla, Narendranath
    Voorhees, Timothy
    Welkie, Rina Li
    Huang, Ying
    Behbehani, Gregory K.
    Zhang, Xiaoli
    McLaughlin, Eric
    Chan, Wing K.
    Brammer, Jonathan E.
    Jaglowski, Samantha
    Reneau, John C.
    Christian, Beth A.
    William, Basem M.
    Cohen, Jonathon B.
    Baiocchi, Robert A.
    Maddocks, Kami
    Blum, Kristie A.
    Alinari, Lapo
    CANCERS, 2023, 15 (05)
  • [29] A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma
    Hanel, Walter
    Christian, Beth A.
    Maddocks, Kami J.
    Epperla, Narendranath
    William, Basem M.
    Jaglowski, Samantha
    Bond, David A.
    Sawalha, Yazeed
    Reneau, John C.
    Brammer, Jonathan E.
    Baiocchi, Robert
    Blum, Kristie A.
    Alinari, Lapo
    BLOOD, 2020, 136
  • [30] Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial
    Jaeger, U.
    Engert, A.
    Fanale, M.
    Santoro, A.
    Armand, P.
    Ansell, S.
    Zinzani, P. L.
    Timmerman, J. M.
    Collins, G. P.
    Ramchandren, R.
    Cohen, J. B.
    De Boer, J. P.
    Kuruvilla, J.
    Savage, K. J.
    Trneny, M.
    Rodig, S.
    Shipp, M.
    Kato, K.
    Sumbul, A.
    Farsaci, B.
    Younes, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 13 - +
12345